UA107329C2 - Туберкульозний білок rv2386c, композиція, що його містить, та застосування - Google Patents

Туберкульозний білок rv2386c, композиція, що його містить, та застосування

Info

Publication number
UA107329C2
UA107329C2 UAA201100300A UAA201100300A UA107329C2 UA 107329 C2 UA107329 C2 UA 107329C2 UA A201100300 A UAA201100300 A UA A201100300A UA A201100300 A UAA201100300 A UA A201100300A UA 107329 C2 UA107329 C2 UA 107329C2
Authority
UA
Ukraine
Prior art keywords
rv2386c
tuberculous
protein
applications
composition containing
Prior art date
Application number
UAA201100300A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джеймс Браун
Паскаль Меттенс
Денніс Мюрфі
Original Assignee
Глаксосмітклайн Байолоджікалз С.А.
Глаксо Груп Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмітклайн Байолоджікалз С.А., Глаксо Груп Лімітед filed Critical Глаксосмітклайн Байолоджікалз С.А.
Publication of UA107329C2 publication Critical patent/UA107329C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
UAA201100300A 2008-07-25 2009-07-24 Туберкульозний білок rv2386c, композиція, що його містить, та застосування UA107329C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25
PCT/EP2009/059585 WO2010010179A1 (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof

Publications (1)

Publication Number Publication Date
UA107329C2 true UA107329C2 (uk) 2014-12-25

Family

ID=41227131

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100300A UA107329C2 (uk) 2008-07-25 2009-07-24 Туберкульозний білок rv2386c, композиція, що його містить, та застосування

Country Status (23)

Country Link
US (4) US20110206712A1 (enExample)
EP (1) EP2315834B1 (enExample)
JP (2) JP5981138B2 (enExample)
KR (1) KR20110049834A (enExample)
CN (2) CN102165064B (enExample)
AU (1) AU2009273132B2 (enExample)
BR (1) BRPI0916704A2 (enExample)
CA (1) CA2731547C (enExample)
CO (1) CO6351811A2 (enExample)
CY (1) CY1121632T1 (enExample)
DK (1) DK2315834T3 (enExample)
EA (1) EA201100070A1 (enExample)
ES (1) ES2685498T3 (enExample)
HR (1) HRP20181353T1 (enExample)
HU (1) HUE039159T2 (enExample)
IL (1) IL210589A (enExample)
LT (1) LT2315834T (enExample)
MX (1) MX2011000982A (enExample)
PL (1) PL2315834T3 (enExample)
PT (1) PT2315834T (enExample)
SI (1) SI2315834T1 (enExample)
UA (1) UA107329C2 (enExample)
WO (1) WO2010010179A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106536A2 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
NO2315597T3 (enExample) 2008-07-25 2018-01-20
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN107478849B (zh) * 2013-05-31 2019-08-20 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2016024129A1 (en) * 2014-08-15 2016-02-18 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
WO2020249756A1 (en) * 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用
WO2026037283A1 (zh) * 2024-08-16 2026-02-19 广州派诺生物技术有限公司 一种用于预防和治疗结核分枝杆菌感染的疫苗及其制备方法
CN120058854A (zh) * 2025-03-05 2025-05-30 北京知筹科技有限公司 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7424370B2 (en) 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
NO2315597T3 (enExample) 2008-07-25 2018-01-20
EP2315773B1 (en) 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
HRP20181353T1 (hr) * 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US8367055B2 (en) 2009-05-14 2013-02-05 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai

Also Published As

Publication number Publication date
IL210589A0 (en) 2011-03-31
JP6104326B2 (ja) 2017-03-29
CA2731547A1 (en) 2010-01-28
US20110206712A1 (en) 2011-08-25
US10286053B2 (en) 2019-05-14
PL2315834T3 (pl) 2018-12-31
LT2315834T (lt) 2018-09-10
CN102165064A (zh) 2011-08-24
CY1121632T1 (el) 2020-07-31
EA201100070A1 (ru) 2011-10-31
CN102165064B (zh) 2017-06-20
MX2011000982A (es) 2011-03-02
US20170065697A1 (en) 2017-03-09
AU2009273132A1 (en) 2010-01-28
US20140314802A1 (en) 2014-10-23
CA2731547C (en) 2019-04-30
BRPI0916704A2 (pt) 2020-08-18
EP2315834B1 (en) 2018-06-13
DK2315834T3 (en) 2018-08-20
HRP20181353T1 (hr) 2018-10-19
SI2315834T1 (sl) 2018-09-28
IL210589A (en) 2015-05-31
PT2315834T (pt) 2018-08-10
JP5981138B2 (ja) 2016-08-31
US9480735B2 (en) 2016-11-01
JP2011528896A (ja) 2011-12-01
KR20110049834A (ko) 2011-05-12
JP2016000734A (ja) 2016-01-07
US20140086948A1 (en) 2014-03-27
EP2315834A1 (en) 2011-05-04
ES2685498T3 (es) 2018-10-09
WO2010010179A1 (en) 2010-01-28
CO6351811A2 (es) 2011-12-20
HUE039159T2 (hu) 2018-12-28
AU2009273132B2 (en) 2015-09-03
CN106866801A (zh) 2017-06-20

Similar Documents

Publication Publication Date Title
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
MX2024014468A (es) Anticuerpos anti-cd63, conjugados y usos de estos
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
WO2012046061A3 (en) Clostridium difficile antigens
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX348071B (es) Variantes de fc.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP4328304A3 (en) Engineered cleavage half-domains
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
PH12012500849A1 (en) Mycobacterial vaccines
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
CA2837395C (en) Immunogenic composition comprising clostridium difficile toxin a and toxin b fusion protein
IN2012DN05145A (enExample)
EP4374913A3 (en) Novel human serum albumin mutant
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
NZ601142A (en) Composition for improving brain function and method for improving brain function